Novartis offers $470 million to acquire US cancer diagnostic firm Genoptix

Published January 24, 2011

Novartis offers 0 million to acquire US cancer diagnostic firm Genoptix
GENEVA – Swiss drug maker Novartis AG says it is paying US$ 470 million to acquire U.S. cancer diagnostic specialist Genoptix Inc. Novartis said Monday it will pay $ 25 per share to acquire all of the Carlsbad, California-based company’s outstanding stock.
Read more on Brandon Sun

Novartis bids 0M for US cancer diagnostic firm
(AP:GENEVA) Swiss drug maker Novartis AG says it is paying $ 470 million to acquire U.S. cancer diagnostic specialist Genoptix Inc. Novartis said Monday it will pay $ 25 per share to acquire all of the Carlsbad, California-based company’s outstanding stock.
Read more on INO News

Novartis bids 0M for California-based cancer diagnostic firm
Swiss drug maker Novartis AG (NYSE: NVS ) says it is paying $ 470 million to acquire U.S. cancer diagnostic specialist Genoptix Inc. Novartis has a growing presence in the Research Triangle Park, N.C. area as it continues to build a huge vaccine production plant in Holly Springs.
Read more on Local Tech Wire